US Patent

US8697860 — Diagnosis and treatment of disease

Formulation · Assigned to Isis Pharmaceuticals Inc · Expires 2031-04-29 · 5y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects methods, compounds, and compositions for reducing transthyretin mRNA and protein expression to treat or prevent transthyretin amyloidosis.

USPTO Abstract

Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.

Drugs covered by this patent

inotersen-sodium (INOTERSEN SODIUM)

Patent Metadata

Patent number: US8697860
Jurisdiction: US
Classification: Formulation
Expires: 2031-04-29
Drug substance claim: No
Drug product claim: Yes
Assignee: Isis Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.